Supernus Pharmaceuticals Inc. (SUPN)
NASDAQ · Healthcare
Supernus Pharmaceuticals Inc. EBITDA 2010–2025
Supernus Pharmaceuticals Inc. annual/quarterly ebitda history and growth rate from 2010 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Supernus Pharmaceuticals Inc. ebitda for the quarter ending March 31, 2026 was 17.8 M, a 75.77% increase year-over-year.
- Supernus Pharmaceuticals Inc. ebitda for the twelve months ending March 31, 2026 was -19.2 M, a 121.07% decrease year-over-year.
- Supernus Pharmaceuticals Inc. annual ebitda for 2025 was 29.3 M, a 81.93% decrease from 2024.
- Supernus Pharmaceuticals Inc. annual ebitda for 2024 was 162.1 M, a 103.64% increase from 2023.
- Supernus Pharmaceuticals Inc. annual ebitda for 2023 was 79.6 M, a 39.55% decrease from 2022.
- Supernus Pharmaceuticals Inc. annual ebitda for 2022 was 131.7 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Supernus Pharmaceuticals Inc. EBITDA — FAQ
Supernus Pharmaceuticals Inc. (SUPN) ebitda over the last 16 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see SUPN's ebitda history?
The chart and table above show Supernus Pharmaceuticals Inc.'s ebitda by year and by quarter, including the growth rate.